Roivant Sciences ROIV stock surged on Friday on positive Phase 2 results for brepocitinib in cutaneous sarcoidosis (CS), an inflammatory skin condition with small bumps and broad, raised skin lesions.

・The company said that the designation is supported by clinical data which demonstrates a 33% objective response rate for pelareorep-based therapy. ・According to Oncolytics, there are an estimated 2 ...